$TCRR
Tcr2 Therapeutics Inc
PRICE
$2.38 ▲1.277%
Last Close
VOLUME
277,344
DAY RANGE
2.3127 - 2.39
52 WEEK
2.1 - 19.85
Key Metrics
Market Cap
90.58 M
Beta
1.50
Avg. Volume
503.69 K
Shares Outstanding
38.55 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
CEO: Garry Menzel
Website: www.tcr2.com
HQ: 100 Binney St Cambridge, 02142-1096 Massachusetts
Related News